BTIM Stock NEws, BioTime CEO Dr. Michael West to Present Keynote Address at China-USA Scientific Forum of Stem Cell and Regenerative Medicine
Sep. 18, 2009 (Business Wire) -- BioTime, Inc. (OTCBB:BTIM stock news) Chief
Executive Officer Michael West, Ph.D. will deliver the keynote
presentation on Tuesday, September 22, 2009 at the China-USA Scientific
Forum of Stem Cell and Regenerative Medicine in Beijing, China. Dr.
West's presentation is titled “The New Era of Regenerative
Medicine—Induced Pluripotent Stem Cells and Beyond.”
Dr.
Walter Funk, BioTime’s Vice President–Stem Cell Research, will speak in
place of Dr. West at the 2009 World Stem Cell Summit meeting in
Baltimore, Maryland on Wednesday, September 23, 2009. Dr. Funk's
presentation is titled “Regenerative Medicine 2.0—Solving the Challenge
of Purity and Identity in Stem Cell Therapies.” The presentation will
address the challenges the regenerative medicine (ReGEN) industry is
currently facing due to cellular contamination producing undesired cell
and tissues at the site of engraftment and the potential use of
BioTime’s purification technology to mitigate this problem.
Dr. Funk's presentation will also include a discussion of PureStem™
cell lines that exhibit markers for becoming embryonic progenitors of
cartilage cells. Dr. West's presentation will be available on September
22, 2009, and Dr. Funk’s presentation will be available online on
September 23, 2009 at http://www.biotimeinc.com.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology
company focused on regenerative medicine and blood plasma volume
expanders. BioTime develops and markets research products in the field
of stem cells and regenerative medicine through its wholly owned
subsidiary Embryome Sciences, Inc. In addition to its stem cell
products, BioTime markets blood plasma volume expanders and related
technology for use in surgery, emergency trauma treatment, and other
applications. BioTime's lead product, Hextend®, is a blood
plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under
exclusive licensing agreements. Additional information about BioTime
can be found on the web at www.biotimeinc.com.
Hextend®,
PentaLyte®, HetaCool®, Embryomics™, ESpy™, ESpan™, ReCyte™, and
PureStem™ are trademarks of BioTime, Inc. ACTCellerate™ is a trademark
licensed to Embryome Sciences, Inc. by Advanced Cell Technology, Inc.
Forward-Looking Statements
Statements
pertaining to future financial and/or operating results, future growth
in research, technology, clinical development and potential
opportunities for the company and its subsidiary, along with other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will,"
"believes," "plans," "anticipates," "expects," "estimates,") should
also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization
of potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on
the following link to join our email alert list:
http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0
